The Human Breast Tissue and Pathology Core (HBTPC) resource provides essential services to all projects in the Johns Hopkins Breast Cancer SPORE in three major areas: tissue acquisition and processing, tissue histology and analysis, and pathologist consultation. As an integral component of our Breast Cancer Program, this Core also provides these services in collaboration with investigators of other SPORE programs, other breast cancer research programs at Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center (SKCCC), and a number of collaborating investigators at other institutions. It is therefore a unique and essential resource. For tissue acquisition and processing, the HBTPC oversees the collection and distribution of fresh and freshfrozen specimens, including samples of invasive carcinoma, in situ carcinoma, metastatic carcinoma, and normal breast from breast cancer patients and from healthy (breast reduction) patients. In addition to prospective collection, the HBTBC has reviewed and catalogued similar specimens that had been collected prior to the SPORE funding and stored in the Pathology Department tissue bank, providing a resource of over 1200 frozen samples. The HBTPC continuously addresses needs of specific projects in the Breast SPORE program, by initiating collection and distribution of peripheral blood and duct lavage specimens, establishing explants for ex vivo testing of novel therapeutic agents, constructing tissue arrays that represent the full spectrum of neoplasia of the breast, and overseeing an immediate autopsy program that harvests tissues from widely metastatic, advanced cancers. For tissue histology, the HBPTC utilizes the existing Reference Histology and Immunohistochemistry laboratories in the Department of Pathology. The Core also uses a tissue microarray laboratory in Pathology and laser microdissection equipment in the Cancer Center, providing these services in an integrated, cost-effective manner. Perhaps the most important contribution of this Core to the Program is that of expert pathologist consultative services. Two pathologists, experienced in both the disciplines of surgical pathology and breast cancer research, work closely with SPORE investigators in experimental design, use of human tissues, and interpretation of data involving analysis of human tissues. These investigators (Drs. Argani and Gabrielson) have co-authored 43 breast cancer publications during the five years of SPORE funding, reflecting their engagement in the program and the contribution of this core to breast cancer research at Johns Hopkins.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA088843-07
Application #
7726895
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2007-09-30
Budget End
2008-09-29
Support Year
7
Fiscal Year
2007
Total Cost
$120,765
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lo, Pang-Kuo (2018) FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells. Trends Diabetes Metab 1:
Cravero, Karen; Medford, Arielle; Pallavajjala, Aparna et al. (2018) Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Pract Lab Med 12:e00108
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Lo, Pang-Kuo (2017) The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer. PRAS Open 1:
Haffner, Michael C; Esopi, David M; Chaux, Alcides et al. (2017) AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun 8:142
Sunay, Melek M E; Foote, Jeremy B; Leatherman, James M et al. (2017) Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol 46:112-123
Parsons, Heather A; Beaver, Julia A; Cimino-Mathews, Ashley et al. (2017) Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23:379-386
Sadik, Helen; Korangath, Preethi; Nguyen, Nguyen K et al. (2016) HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res 76:4443-56
Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc et al. (2016) Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 7:6281-93

Showing the most recent 10 out of 282 publications